Watchlist Manager

Watchlist

Price: 1 446 JPY 1.26%

Market Cap: ¥13.5B

	Immuno-Biological Laboratories Co Ltd TSE:4570	JP
N	NXP Semiconductors NV SWB:VNX	NL
G	Geely Automobile Holdings Ltd XBER:GRU	HK
	China Construction Bank Corp SSE:601939	CN

Income Statement

Currency: JPY

	Dec-2007	Jun-2008	Sep-2008	Dec-2008	Jun-2009	Sep-2009	Dec-2009	Jun-2010	Sep-2010	Dec-2010	Mar-2011	Jun-2011	Sep-2011	Dec-2011	Mar-2012	Jun-2012	Sep-2012	Dec-2012	Mar-2013	Jun-2013	Sep-2013	Dec-2013	Mar-2014	Jun-2014	Sep-2014	Dec-2014	Mar-2015	Jun-2015	Sep-2015	Dec-2015	Mar-2016	Jun-2016	Sep-2016	Dec-2016	Mar-2017	Jun-2017	Sep-2017	Dec-2017	Mar-2018	Jun-2018	Sep-2018	Dec-2018	Mar-2019	Jun-2019	Sep-2019	Dec-2019	Mar-2020	Jun-2020	Sep-2020	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024	Jun-2024	Sep-2024	Dec-2024	Mar-2025	Jun-2025	Sep-2025	Dec-2025
Revenue
Interest Expense	0	0	0	0	0	0	0	0	1	1	2	2	2	2	2	2	1	1	2	2	2	2	2	2	2	2	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0
Revenue	745 N/A	693 -7%	754 +9%	764 +1%	763 0%	686 -10%	708 +3%	735 +4%	758 +3%	804 +6%	1 060 +32%	1 015 -4%	965 -5%	882 -9%	915 +4%	913 0%	894 -2%	852 -5%	800 -6%	713 -11%	664 -7%	674 +2%	670 -1%	682 +2%	711 +4%	666 -6%	729 +9%	735 +1%	715 -3%	781 +9%	718 -8%	734 +2%	797 +9%	745 -7%	742 0%	734 -1%	725 -1%	735 +1%	758 +3%	797 +5%	809 +2%	832 +3%	781 -6%	723 -7%	628 -13%	592 -6%	577 -3%	580 +1%	594 +2%	601 +1%	603 +0%	611 +1%	609 0%	636 +5%	648 +2%	679 +5%	687 +1%	754 +10%	795 +5%	815 +3%	867 +6%	788 -9%	817 +4%	869 +6%	895 +3%	948 +6%	970 +2%	951 -2%	1 011 +6%	1 032 +2%
Gross Profit
Cost of Revenue	(421)	(410)	(409)	(441)	(435)	(411)	(399)	(397)	(408)	(398)	(488)	(443)	(400)	(334)	(339)	(344)	(321)	(325)	(323)	(298)	(300)	(290)	(298)	(306)	(325)	(321)	(362)	(322)	(312)	(325)	(266)	(300)	(311)	(313)	(327)	(328)	(309)	(302)	(281)	(293)	(315)	(307)	(321)	(309)	(279)	(290)	(359)	(356)	(361)	(349)	(256)	(257)	(263)	(267)	(271)	(271)	(262)	(261)	(268)	(282)	(298)	(299)	(299)	(300)	(313)	(317)	(335)	(319)	(316)	(306)
Gross Profit	325 N/A	283 -13%	345 +22%	323 -6%	328 +2%	275 -16%	310 +13%	338 +9%	350 +4%	406 +16%	571 +41%	573 +0%	565 -1%	548 -3%	576 +5%	569 -1%	572 +1%	527 -8%	477 -9%	415 -13%	364 -12%	384 +5%	372 -3%	376 +1%	386 +3%	345 -11%	367 +6%	413 +13%	403 -2%	457 +13%	452 -1%	434 -4%	486 +12%	431 -11%	415 -4%	406 -2%	416 +2%	433 +4%	477 +10%	504 +6%	494 -2%	525 +6%	460 -12%	413 -10%	348 -16%	302 -13%	217 -28%	224 +3%	233 +4%	252 +8%	347 +38%	355 +2%	346 -2%	370 +7%	377 +2%	407 +8%	425 +4%	493 +16%	527 +7%	533 +1%	569 +7%	489 -14%	517 +6%	569 +10%	582 +2%	631 +8%	634 +1%	632 0%	695 +10%	726 +4%
Operating Income
Operating Expenses	(682)	(669)	(675)	(667)	(631)	(589)	(543)	(534)	(530)	(524)	(636)	(598)	(557)	(539)	(553)	(521)	(497)	(477)	(469)	(456)	(483)	(473)	(480)	(494)	(484)	(532)	(555)	(573)	(587)	(551)	(527)	(535)	(566)	(606)	(1 719)	(1 572)	(1 515)	(1 473)	(526)	(529)	(541)	(574)	(634)	(655)	(694)	(709)	(813)	(817)	(796)	(779)	(588)	(568)	(546)	(517)	(499)	(471)	(465)	(460)	(468)	(459)	(441)	(439)	(413)	(414)	(424)	(413)	(425)	(420)	(412)	(418)
Selling, General & Administrative	(682)	(582)	(500)	(419)	(394)	(370)	(324)	(320)	(305)	(299)	(342)	(414)	(453)	(507)	(303)	(520)	(497)	(477)	(252)	(456)	(482)	(473)	(290)	(493)	(484)	(526)	(348)	(566)	(580)	(551)	(313)	(517)	(549)	(589)	(310)	(1 572)	(1 515)	(1 473)	(353)	(529)	(541)	(574)	(397)	(656)	(694)	(709)	(494)	(817)	(796)	(779)	(321)	(568)	(546)	(517)	(310)	(471)	(465)	(460)	(289)	(459)	(441)	(439)	(281)	(414)	(424)	(413)	(300)	(420)	(412)	(418)
Research & Development	0	(88)	(175)	(248)	(237)	(219)	(219)	(214)	(225)	(225)	(256)	0	0	0	(221)	0	0	0	(190)	0	0	0	(153)	0	0	0	(159)	0	0	0	0	0	0	0	(1 240)	0	0	0	(173)	0	0	0	(237)	0	0	0	(318)	0	0	0	(267)	0	0	0	(189)	0	0	0	(180)	0	0	0	(130)	0	0	0	(119)	0	0	0
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0	(38)	0	0	0	(29)	0	0	0	(26)	0	0	0	(38)	0	0	(7)	0	0	0	0	(22)	0	0	0	(170)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(2)	0	0	0	(6)	0	0	0
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0	0	(184)	(104)	(31)	0	0	0	0	0	0	0	0	0	0	0	0	(48)	(7)	(6)	0	(193)	(17)	(17)	(17)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(0)	0	(0)	(0)	(0)	(0)	(0)	(0)	(0)	0	(0)	0	(0)	(0)	(0)	(0)
Operating Income	(358) N/A	(386) -8%	(330) +15%	(345) -4%	(303) +12%	(314) -3%	(234) +25%	(195) +16%	(180) +8%	(118) +35%	(64) +45%	(25) +61%	7 N/A	9 +25%	24 +161%	48 +105%	75 +56%	49 -34%	9 -83%	(41) N/A	(118) -186%	(89) +25%	(108) -21%	(118) -9%	(99) +16%	(187) -90%	(188) -1%	(159) +15%	(183) -15%	(95) +48%	(75) +21%	(101) -34%	(80) +21%	(175) -118%	(1 305) -647%	(1 166) +11%	(1 100) +6%	(1 040) +5%	(49) +95%	(25) +49%	(47) -88%	(48) -3%	(174) -261%	(242) -39%	(346) -43%	(407) -18%	(595) -46%	(592) +0%	(563) +5%	(527) +6%	(241) +54%	(213) +12%	(200) +6%	(147) +27%	(122) +17%	(63) +48%	(40) +36%	33 N/A	58 +75%	74 +26%	128 +73%	50 -61%	104 +108%	155 +49%	158 +2%	218 +38%	209 -4%	212 +1%	283 +34%	308 +9%
Pre-Tax Income
Interest Income Expense	(0)	(4)	(7)	(7)	(3)	1	(5)	(9)	(9)	(6)	(7)	(3)	(4)	(4)	(2)	(4)	(4)	85	86	87	76	(7)	(6)	(7)	12	16	11	82	73	64	62	(16)	(17)	(7)	(4)	4	6	(3)	(3)	(1)	2	0	4	(21)	(44)	(65)	(96)	(102)	(108)	(110)	(87)	(91)	(90)	(111)	(150)	(161)	(174)	(140)	(199)	(150)	(110)	(102)	8	6	(6)	5	(4)	(10)	3	(0)
Non-Reccuring Items	(4)	5	5	8	2	2	2	6	(2)	(15)	(40)	(55)	(47)	(34)	(9)	(0)	(0)	(0)	(1)	0	0	0	(0)	0	(0)	(0)	(0)	0	0	0	(17)	0	0	0	(771)	(919)	(919)	(921)	(3)	(11)	(11)	(8)	(8)	4	4	4	4	(0)	(0)	(0)	(0)	(7)	(7)	(5)	(7)	(2)	(2)	(4)	(192)	(191)	(191)	(191)	(1)	0	0	0	0	0	0	0
Gain/Loss on Disposition of Assets	0	(3)	(3)	(3)	0	0	0	0	0	(23)	(23)	0	0	0	0	0	(2)	(2)	(2)	(3)	(0)	(0)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	16	16	0	0	0	0	0	0	0	0	0	0	0	46	0	0	0	0	0	0	0	0	0	0	0
Total Other Income	1	(9)	3	3	4	2	4	2	9	9	34	12	8	28	34	104	102	102	72	2	(1)	(3)	2	10	28	37	16	8	(4)	(10)	1	(1)	(5)	(14)	(10)	(8)	(6)	5	3	2	1	(2)	14	15	15	29	13	32	33	8	17	20	19	15	29	27	29	28	6	55	54	56	13	7	8	6	4	9	9	9
Pre-Tax Income	(361) N/A	(397) -10%	(333) +16%	(343) -3%	(301) +12%	(309) -3%	(233) +25%	(196) +16%	(183) +7%	(153) +16%	(99) +35%	(71) +28%	(37) +48%	(0) +99%	46 N/A	147 +223%	171 +16%	234 +37%	163 -30%	45 -72%	(43) N/A	(99) -131%	(112) -13%	(115) -2%	(59) +49%	(134) -129%	(161) -20%	(69) +57%	(114) -64%	(41) +64%	(30) +27%	(118) -301%	(101) +14%	(195) -93%	(2 089) -969%	(2 089) +0%	(2 019) +3%	(1 959) +3%	(52) +97%	(35) +32%	(55) -56%	(58) -5%	(164) -184%	(244) -49%	(371) -52%	(423) -14%	(659) -56%	(663) -1%	(639) +4%	(629) +2%	(311) +51%	(292) +6%	(278) +5%	(248) +11%	(250) -1%	(198) +21%	(187) +6%	(82) +56%	(281) -241%	(211) +25%	(119) +44%	(186) -56%	125 N/A	168 +35%	159 -6%	229 +44%	210 -8%	211 +0%	295 +40%	317 +7%
Net Income
Tax Provision	(24)	(71)	(2)	(2)	(2)	(2)	(2)	(2)	(3)	(3)	(4)	(4)	(3)	(3)	(3)	(8)	(8)	(7)	(10)	(5)	(6)	(6)	(6)	(6)	(6)	(7)	(5)	(11)	(5)	(7)	(2)	4	(2)	0	(6)	(5)	(5)	(5)	(1)	(1)	(3)	(3)	(3)	(3)	(5)	(6)	(9)	(10)	(6)	(6)	(8)	(9)	(10)	(10)	(9)	(9)	(9)	(9)	(9)	(8)	(8)	(7)	62	58	72	71	39	48	24	47
Income from Continuing Operations	(385)	(468)	(335)	(345)	(303)	(311)	(235)	(198)	(185)	(156)	(104)	(75)	(40)	(3)	43	139	163	226	153	40	(49)	(106)	(118)	(121)	(65)	(141)	(166)	(80)	(119)	(48)	(32)	(115)	(104)	(195)	(2 094)	(2 094)	(2 024)	(1 964)	(53)	(36)	(58)	(60)	(167)	(247)	(376)	(429)	(668)	(673)	(644)	(635)	(319)	(300)	(288)	(259)	(259)	(207)	(196)	(92)	(290)	(220)	(127)	(193)	187	227	231	299	249	259	319	364
Income to Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	5	8	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income (Common)	(385) N/A	(468) -21%	(335) +28%	(345) -3%	(303) +12%	(311) -3%	(235) +24%	(198) +16%	(185) +6%	(156) +16%	(104) +34%	(75) +28%	(40) +46%	(3) +92%	43 N/A	139 +225%	163 +17%	226 +39%	153 -32%	40 -74%	(49) N/A	(106) -118%	(115) -9%	(116) -1%	(57) +51%	(131) -129%	(158) -21%	(75) +53%	(116) -55%	(47) +59%	(32) +32%	(115) -260%	(104) +10%	(195) -89%	(2 094) -972%	(2 094) +0%	(2 024) +3%	(1 964) +3%	(53) +97%	(36) +32%	(58) -60%	(60) -5%	(167) -178%	(247) -48%	(376) -52%	(429) -14%	(668) -56%	(673) -1%	(644) +4%	(635) +1%	(319) +50%	(300) +6%	(288) +4%	(259) +10%	(259) 0%	(207) +20%	(196) +5%	(92) +53%	(290) -216%	(220) +24%	(127) +42%	(193) -52%	187 N/A	227 +22%	231 +2%	299 +29%	249 -17%	259 +4%	319 +23%	364 +14%
EPS (Diluted)	-62.14 N/A	-75.43 -21%	-54.06 +28%	-55.66 -3%	-48.87 +12%	-50.16 -3%	-37.93 +24%	-31.91 +16%	-29.85 +6%	-25.11 +16%	-16.69 +34%	-12.06 +28%	-6.46 +46%	-0.54 +92%	6.9 N/A	22.45 +225%	26.27 +17%	36.51 +39%	24.69 -32%	6.51 -74%	-7.69 N/A	-16.23 -111%	-17.92 -10%	-17.81 +1%	-8.78 +51%	-20.13 -129%	-24.21 -20%	-11.52 +52%	-17.89 -55%	-7.26 +59%	-4.86 +33%	-15.95 -228%	-14.17 +11%	-26.76 -89%	-287.53 -974%	-282.94 +2%	-273.5 +3%	-265.37 +3%	-7.01 +97%	-4.27 +39%	-6.84 -60%	-7.15 -5%	-19.83 -177%	-28.33 -43%	-43.14 -52%	-49.13 -14%	-76.01 -55%	-72.21 +5%	-69.16 +4%	-68.13 +1%	-34.23 +50%	-32.26 +6%	-30.88 +4%	-27.76 +10%	-27.78 0%	-22.22 +20%	-21 +5%	-9.84 +53%	-31.11 -216%	-23.58 +24%	-13.6 +42%	-20.69 -52%	20.05 N/A	24.36 +21%	24.84 +2%	32.15 +29%	26.74 -17%	27.77 +4%	34.27 +23%	39.07 +14%

Income Statement Balance Sheet Cash Flow Statement

Immuno-Biological Laboratories Co Ltd
TSE:4570

Income Statement

Earnings Waterfall
Immuno-Biological Laboratories Co Ltd

Income Statement
Immuno-Biological Laboratories Co Ltd

See Also

Company

Help

Tools

Stocks

Immuno-Biological Laboratories Co Ltd TSE:4570

Income Statement

Earnings Waterfall Immuno-Biological Laboratories Co Ltd

Income Statement Immuno-Biological Laboratories Co Ltd

See Also

Company

Help

Tools

Stocks

Immuno-Biological Laboratories Co Ltd
TSE:4570

Earnings Waterfall
Immuno-Biological Laboratories Co Ltd

Income Statement
Immuno-Biological Laboratories Co Ltd